Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Clinical Journal of the American Society of Nephrology Year : 2023

Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases

Abstract

Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with non-kidney clearance being predominant. Due to their limited therapeutic window, many TKI display considerable intra- and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as acute kidney injury (AKI) and chronic kidney disease (CKD), among cancer patients is explored in terms of their impact on TKI pharmacokinetics. Lastly, the potential nephrotoxicity associated with TKI is also examined.
Fichier principal
Vignette du fichier
PKPD.TKI.CJASN.subimission revised version 5_clean.pdf (631.45 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04347296 , version 1 (15-12-2023)

Identifiers

Cite

Anne Hulin, Thibaut Gelé, Charlotte Fenioux, Emmanuelle Kempf, Dil Sahali, et al.. Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases. Clinical Journal of the American Society of Nephrology, 2023, ⟨10.2215/CJN.0000000000000395⟩. ⟨hal-04347296⟩
13 View
83 Download

Altmetric

Share

Gmail Facebook X LinkedIn More